Literature DB >> 32298491

Progress on ocular siRNA gene-silencing therapy and drug delivery systems.

Jinjin Jiang1,2, Xinru Zhang1,2, Yue Tang1,2, Shuhan Li2, Jing Chen2.   

Abstract

Age-related macular degeneration (AMD) and glaucoma are global ocular diseases with high blindness rate. RNA interference (RNAi) is being increasingly used in the treatment of these disorders with siRNA drugs, bevasiranib, AGN211745 and PF-04523655 for AMD, and SYL040012 and QPI-1007 for glaucoma. Administration routes and vectors of gene drugs affect their therapeutic effect. Compared with the non-viral vectors, viral vectors have limited payload capacity and potential immunogenicity. This review summarizes the progress of the ocular siRNA gene-silencing therapy by focusing on siRNA drugs for AMD and glaucoma already used in clinical research, the main routes of drug delivery and the non-viral vectors for siRNA drugs.
© 2020 Société Française de Pharmacologie et de Thérapeutique.

Entities:  

Keywords:  RNA interference technology; age-related macular degeneration; glaucoma; non-viral vectors; siRNA drugs

Year:  2020        PMID： 32298491     DOI： 10.1111/fcp.12561

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN： 0767-3981            Impact factor:   2.748


  11 in total

Review 1.  Extracellular Vesicles in Corneal Fibrosis/Scarring.

Authors:  Vincent Yeung; Nikolay Boychev; Wissam Farhat; Dimitrios P Ntentakis; Audrey E K Hutcheon; Amy E Ross; Joseph B Ciolino
Journal:  Int J Mol Sci       Date:  2022-05-25       Impact factor: 6.208

Review 2.  Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses.

Authors:  Hashem H Ghoraba; Amir Akhavanrezayat; Irmak Karaca; Negin Yavari; Sherin Lajevardi; Jaclyn Hwang; Jonathan Regenold; Wataru Matsumiya; Brandon Pham; Moosa Zaidi; Azadeh Mobasserian; Anthony Toan DongChau; Christopher Or; Cigdem Yasar; Kapil Mishra; Diana Do; Quan Dong Nguyen
Journal:  Clin Ophthalmol       Date:  2022-06-03

Review 3.  The growth of siRNA-based therapeutics: Updated clinical studies.

Authors:  M May Zhang; Raman Bahal; Theodore P Rasmussen; José E Manautou; Xiao-Bo Zhong
Journal:  Biochem Pharmacol       Date:  2021-01-26       Impact factor: 6.100

Review 4.  RNA therapeutics for retinal diseases.

Authors:  Michael C Gemayel; Ashay D Bhatwadekar; Thomas Ciulla
Journal:  Expert Opin Biol Ther       Date:  2020-12-16       Impact factor: 5.589

5.  Novel use of a chemically modified siRNA for robust and sustainable in vivo gene silencing in the retina.

Authors:  Takazumi Taniguchi; Ken-Ichi Endo; Hidetoshi Tanioka; Masaaki Sasaoka; Kei Tashiro; Shigeru Kinoshita; Masaaki Kageyama
Journal:  Sci Rep       Date:  2020-12-18       Impact factor: 4.379

6.  Efficient Ocular Delivery of VCP siRNA via Reverse Magnetofection in RHO P23H Rodent Retina Explants.

Authors:  Merve Sen; Marco Bassetto; Florent Poulhes; Olivier Zelphati; Marius Ueffing; Blanca Arango-Gonzalez
Journal:  Pharmaceutics       Date:  2021-02-06       Impact factor: 6.321

Review 7.  The Alter Retina: Alternative Splicing of Retinal Genes in Health and Disease.

Authors:  Izarbe Aísa-Marín; Rocío García-Arroyo; Serena Mirra; Gemma Marfany
Journal:  Int J Mol Sci       Date:  2021-02-12       Impact factor: 5.923

Review 8.  Topical Medication Therapy for Glaucoma and Ocular Hypertension.

Authors:  Tao Wang; Linlin Cao; Qikun Jiang; Tianhong Zhang
Journal:  Front Pharmacol       Date:  2021-12-01       Impact factor: 5.810

9.  Hydrogel-metal-organic-framework hybrids mediated efficient oral delivery of siRNA for the treatment of ulcerative colitis.

Authors:  Meng Gao; Chen Yang; Chenghu Wu; Yue Chen; Hongqin Zhuang; Jilong Wang; Zhiting Cao
Journal:  J Nanobiotechnology       Date:  2022-09-05       Impact factor: 9.429

10.  Novel PEGylated Lipid Nanoparticles Have a High Encapsulation Efficiency and Effectively Deliver MRTF-B siRNA in Conjunctival Fibroblasts.

Authors:  Amisha Sanghani; Konstantinos N Kafetzis; Yusuke Sato; Salsabil Elboraie; Julia Fajardo-Sanchez; Hideyoshi Harashima; Aristides D Tagalakis; Cynthia Yu-Wai-Man
Journal:  Pharmaceutics       Date:  2021-03-13       Impact factor: 6.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.